You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Xeloda

Showing 1 - 25 of 771
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Biliary Tract Cancer Trial in Kaohsiung, Taichung (D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX)

Recruiting
  • Biliary Tract Cancer
  • D07001-softgel capsules + Xeloda (or TS-1)
  • mFOLFOX
  • Kaohsiung, Taiwan
  • +4 more
Dec 22, 2022

Pancreas Cancer, Pancreas Adenocarcinoma Trial in Cleveland (Capecitabine)

Not yet recruiting
  • Pancreas Cancer
  • Pancreas Adenocarcinoma
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Seidman Cancer Ce
Oct 29, 2023

Gastrointestinal Cancer Trial (Capecitabine, Sacituzumab govetican)

Not yet recruiting
  • Gastrointestinal Cancer
  • (no location specified)
Oct 2, 2023

Metastatic Breast Cancer Trial in Birmingham (Capecitabine Pill)

Not yet recruiting
  • Metastatic Breast Cancer
  • Capecitabine Pill
  • Birmingham, Alabama
    University of Alabama at Birmingham
Oct 23, 2023

Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Residual Disease
  • (no location specified)
Nov 15, 2023

Rectal Adenocarcinoma Trial in Tampa (Capecitabine, Radiation Therapy, FOLFOX regimen)

Recruiting
  • Rectal Adenocarcinoma
  • Tampa, Florida
    Moffitt Cancer Center
Jan 24, 2023

Colonic Tumors, Neoadjuvant Therapy, Immune Checkpoint Inhibitors Trial in Nanning (Tislelizumab, Oxaliplatin, Capecitabine)

Recruiting
  • Colonic Neoplasms
  • +2 more
  • Nanning, Guangxi, China
    The First Affiliated Hospital of Guangxi Medical University
Nov 9, 2023

Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)

Not yet recruiting
  • Triple Negative Breast Neoplasms
  • Pembrolizumab injection
  • +2 more
  • (no location specified)
Jul 25, 2023

Gastroesophageal Junction (GEJ) Adenocarcinoma Trial in Beijing (Q-1802 Injection,Oxaliplatin Injection,Capecitabine)

Recruiting
  • Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Q-1802 Injection,Oxaliplatin Injection,Capecitabine
  • Beijing, Beijing, China
    Beijing cancer hospical
Jul 27, 2023

Breast Cancer, Triple Negative Breast Cancer Trial in United States (Capecitabine, Talazoparib, Atezolizumab)

Recruiting
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Washington, District of Columbia
  • +5 more
Jan 12, 2023

Gastroesophageal Junction Adenocarcinoma Trial in Shijiazhuang (Oxaliplatin; Capecitabine, Oxaliplatin; Capecitabine; concurrent

Completed
  • Gastroesophageal Junction Adenocarcinoma
  • Oxaliplatin; Capecitabine
  • Oxaliplatin; Capecitabine; concurrent radiotherapy
  • Shijiazhuang, Hebei, China
    Department of General Surgery
Feb 4, 2022

pMMR, MSS, MSI-L Trial (Serplilumab, Capecitabine, Oxaliplatin)

Not yet recruiting
  • pMMR
  • +3 more
  • (no location specified)
Feb 19, 2023

Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)

Recruiting
  • Hormone Receptor-positive Breast Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Anal Squamous Cell Carcinoma Trial in New York (Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and

Recruiting
  • Anal Squamous Cell Carcinoma
  • Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery
  • +3 more
  • New York, New York
    Columbia University Irving Medical Center
Apr 27, 2023

Early Low Rectal Cancer Trial in Shanghai (PD-1 antibody, Capecitabine, Oxaliplatin)

Recruiting
  • Early Low Rectal Cancer
  • PD-1 antibody
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jan 9, 2023

Locally Advanced Colon Cancer Trial (Serplulimab, short-term radiotherapy, Oxaliplatin)

Not yet recruiting
  • Locally Advanced Colon Cancer
  • (no location specified)
Feb 16, 2023

Recurrent Rectal Cancer Trial in Shanghai (PD-1 antibody, Capecitabine, Oxaliplatin)

Not yet recruiting
  • Recurrent Rectal Cancer
  • PD-1 antibody
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 17, 2022

Locally Advanced Rectal Cancer Trial (PD-1 inhibitor, Capecitabine, Long-course radiation therapy)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • PD-1 inhibitor
  • +2 more
  • (no location specified)
Aug 16, 2022

Pancreatic Cancer Trial in Singapore (oxaliplatin, irinotecan, capecitabine)

Completed
  • Pancreatic Cancer
  • oxaliplatin, irinotecan, capecitabine
  • Singapore, Singapore
    National Cancer Centre
May 28, 2021

Cancer of Pancreas Trial in Cairo (Capecitabine, follow up)

Recruiting
  • Cancer of Pancreas
  • Cairo, Egypt
  • +2 more
Sep 30, 2022

Colo-rectal Cancer, Metastatic Cancer Trial in Besançon, Dijon, Montbéliard (Regorafenib, Cyclophosphamide, Capecitabine)

Active, not recruiting
  • Colo-rectal Cancer
  • Metastatic Cancer
  • Besançon, France
  • +2 more
Jan 24, 2023

Colon Cancer Trial in Oslo (Capecitabine)

Active, not recruiting
  • Colon Cancer
  • Oslo, Norway
    Oslo University Hospital
Apr 19, 2022

Triple Negative Breast Cancer Trial in Guangzhou (Capecitabine, Tucidinostat)

Recruiting
  • Triple Negative Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-yat sen university cancer center
Nov 1, 2022

Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

Active, not recruiting
  • Breast Cancer
  • Guangzhou, Guangdong, China
    State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023